RT Journal Article
SR Electronic
T1 A Genetics-First Approach to Dissecting the Heterogeneity of Autism: Phenotypic Comparison of Autism Risk Copy Number Variants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.01.14.20017426
DO 10.1101/2020.01.14.20017426
A1 Samuel J.R.A. Chawner
A1 Joanne L. Doherty
A1 Richard Anney
A1 Kevin M. Antshel
A1 Carrie E. Bearden
A1 Raphael Bernier
A1 Wendy K. Chung
A1 Caitlin C. Clements
A1 Sarah R. Curran
A1 Goran Cuturilo
A1 Ania M. Fiksinski
A1 Louise Gallagher
A1 Robin P. Goin-Kochel
A1 Raquel E. Gur
A1 Ellen Hanson
A1 Sebastien Jacquémont
A1 Wendy R. Kates
A1 Anne M. Maillard
A1 Donna M. McDonald-McGinn
A1 Marina Mihaljevic
A1 Judith S Miller
A1 Hayley Moss
A1 Milica Pejovic-Milovancevic
A1 Robert T. Schultz
A1 LeeAnne G. Snyder
A1 Jacob A. Vorstman
A1 Tara L. Wenger
A1 Jeremy Hall
A1 Michael J. Owen
A1 IMAGINE-ID Consortium
A1 Marianne B.M. van den Bree
YR 2020
UL http://medrxiv.org/content/early/2020/01/31/2020.01.14.20017426.abstract
AB Objective Certain copy number variants (CNVs) greatly increase risk of autism. We conducted a genetics-first study to investigate whether heterogeneity in the clinical presentation of autism is underpinned by specific genotype-phenotype relationships.Methods This international study included 566 children (12.3 years (SD=4.2), 51% male) who were ascertained on the basis of having a genetic diagnosis of a rare CNV associated with high risk of autism (83 16p11.2 deletion carriers, 50 16p11.2 duplication carriers, 380 22q11.2 deletion carriers and 53 22q11.2 duplication carriers), as well as 2027 children (9.1 years (SD=4.9), 87% male) with autism of heterogeneous aetiology. The Autism Diagnostic Interview-Revised (ADI-R) and IQ testing were conducted.Results The four genetic variant groups differed in autism severity, autism subdomain profile as well as IQ profile. However, we found substantial variability in phenotypic outcome within individual genetic variant groups (75% to 96% of the variance depending on the trait), whereas variability between groups was low (1% to 21% depending on trait). We compared CNV carriers who met autism criteria, to children with heterogeneous autism, and a range of profile differences were identified. Using clinical cut-offs, we found that 54% of children with one of the 4CNVs who did not meet full autism diagnostic criteria nonetheless had elevated levels of autistic traits.Conclusion Many CNV carriers do not meet full diagnostic criteria for autism, but nevertheless meet clinical cut-offs for autistic traits. Although we find profile differences between variants, there is considerable variability in clinical symptoms within the same variant.Competing Interest StatementJH reports grants from Wyeth, Pfizer, AbbVie, A&Z Pharmaceutical, and Takeda Pharmaceuticals outside of the submitted work. MJO and MBMvdB report grants from Takeda Pharmaceuticals outside of the submitted work. All other authors declare no competing interests.Funding StatementThis study was funded by the Baily Thomas Charitable Trust (MBMvdB, 2315/1), the Waterloo Foundation (MBMvdB, WF918-1234), Wellcome Trust ISSF grant (MBMvdB), the National Institute for Mental Health (MBMvdB, 5UO1MH101724; WRK, NIH / MH064824; CEB, RO1 MH085953 and U01MH101719), Medical Research Council studentship (SJRAC, 1499282), Wellcome Trust Fellowship (JLD, 505714), Wellcome Trust Strategic Award (MJO, 503147), Health & Care Research Wales (MJO, Welsh Government, 507556), Medical Research Council Centre grant (MJO, G0801418), Medical Research Council Programme grant (MJO, G0800509), the Simons Foundation (CEB, SFARI Explorer Award), Brain Canada foundation (SJ), Canadian Institute of Health Research (SJ, 400528 /159734, Canadian Institute of Health Research (SJ), Canada Research Chair in Genetics of Neurodevelopmental Disorders (SJ), Simons Foundation Autism Research Initiative (WKC), Swiss National Science Foundation (AM, grant PMPDP3_171331), UK Medical Research Council and Medical Research Foundation grants (IMAGINE-ID study MBMvdB, JH & MJO; MR/L011166/1 and MR/N022572/1), and the collaboration with Serbia was funded by the European Cooperation in Science and Technology (MM, MBMvdB, SJRAC; COST action, CA16210).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to ethical restrictions, data is not available to be shared.